Brief: Processa Pharmaceuticals Successfully Identifies Next Generation Capecitabine Dosage Regimens For Phase 2B Trial

Processa Pharmaceuticals

01/11/2022 13:08

Nov 1 (Reuters) - Processa Pharmaceuticals Inc  PCSA.O :
    * PROCESSA SUCCESSFULLY IDENTIFIES NEXT GENERATION
CAPECITABINE
DOSAGE REGIMENS FOR PHASE 2B TRIAL
    * PROCESSA PHARMACEUTICALS INC- IN 2023 CO PLANS TO MEET
WITH FDA
TO DISCUSS DESIGN OF PHASE 2B TRIAL AND INITIATE TRIAL

Source text for Eikon:  ID:nGNXkVmTf 
Further company coverage:  PCSA.O 
 ((Reuters.Briefs@thomsonreuters.com;))